RxDoctor Payments Data

William Shaffer, MD

Nephrology · Corpus Christi, TXNPI 1972506913

Payments from drug & device makers

$1,762in general payments, 2019–2025

Across 92 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$448
  • Amgen$375
  • AstraZeneca$263
  • Novartis$125
  • Johnson & Johnson$113
  • Calliditas Therapeutics US Inc.$76
  • plus $362 from 11 others

What the payments were for

  • Food & beverage$1,73799%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,762 in reported general payments places this provider in the 50th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$164,665
Medicare patients
271
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin305$248,465
FarxigaDapagliflozin Propanediol310$223,360
KerendiaFinerenone162$145,816
FilspariSparsentan13$140,236
VelphoroSucroferric Oxyhydroxide24$62,109
OzempicSemaglutide31$34,388
Sevelamer Carbonate89$26,997
DapagliflozinDapagliflozin Propanediol25$12,680
InvokanaCanagliflozin14$12,666
SpsSodium Polystyrene Sulfon/Sorb23$7,153
Calcium Acetate98$6,865
Midodrine Hcl22$5,225
Labetalol Hcl260$3,315
Losartan Potassium361$2,183
Potassium Chloride39$1,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$38$248,465305 claims
AstraZenecaFarxiga$263$223,360310 claims
BayerKerendia$448$145,816162 claims
Travere Therapeutics, Inc.Filspari$46$140,23613 claims
Fresenius USA Marketing, Inc.Velphoro$31$62,10924 claims
Novo NordiskOzempic$15$34,38831 claims
Johnson & JohnsonInvokana$113$12,66614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →